JAD Introduces New Section: Ethics Review

JAD has launched a new feature, “Ethics Review,” which will provide support and guidance to move ethical decision-making forward. The goal is to create a forum for dementia researchers, clinicians and policy makers to bring greater clarity and constructive discussion to define risks and benefits from the perspectives of diverse disciplines.


New Therapeutic Target Discovered for Alzheimer's Disease

A team from the University of California, San Diego School of Medicine, the Medical University of South Carolina and San Diego-based American Life Science Pharmaceuticals, Inc., report that cathepsin B gene knockout or its reduction by an enzyme inhibitor blocks creation of key neurotoxic pGlu-Aβ peptides linked to Alzheimer’s disease.


No front page content has been created yet.